Naoya Masumori

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Naoya Masumori, T Z Thomas, Pierre Chaurand et al. · PubMed · 2001 · 231 citations

Immunology, Progressive Ne Differentiation, Pathology +16

Serum prostate‐specific antigen in a community‐based population of healthy Japanese men: lower values than for similarly aged white men

Joseph E. Oesterling, Y Kumamoto, Tadashi Tsukamoto et al. · British Journal of Urology · 1995 · 218 citations · Full text

Habitual Intake of Lactic Acid Bacteria and Risk Reduction of Bladder Cancer

Yasuo Ohashi, S. Nakai, Taiji Tsukamoto et al. · Urologia Internationalis · 2002 · 209 citations